Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELYM NASDAQ:IRD NASDAQ:LPTX NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELYMEliem Therapeutics$12.18+6.4%$10.49$2.35▼$11.55$362.38M-0.39486,688 shs1.43 million shsIRDOpus Genetics$4.08$4.66$0.90▼$5.81$336.87M0.56812,070 shs726,713 shsLPTXLeap Therapeutics$2.05$0.00▼$0.00$84.95M-0.0640.67 million shs760.56 million shsUPBUpstream Bio$6.32+0.3%$8.26$5.85▼$33.68$342.85M1.1640,429 shs623,890 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELYMEliem Therapeutics+6.38%+6.01%+10.73%+86.24%+906.61%IRDOpus Genetics0.00%+4.62%-4.23%-14.11%+350.23%LPTXLeap Therapeutics0.00%0.00%0.00%0.00%+204,999,900.00%UPBUpstream Bio+0.32%+6.76%-24.49%-33.26%-41.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELYMEliem Therapeutics$12.18+6.4%$10.49$2.35▼$11.55$362.38M-0.39486,688 shs1.43 million shsIRDOpus Genetics$4.08$4.66$0.90▼$5.81$336.87M0.56812,070 shs726,713 shsLPTXLeap Therapeutics$2.05$0.00▼$0.00$84.95M-0.0640.67 million shs760.56 million shsUPBUpstream Bio$6.32+0.3%$8.26$5.85▼$33.68$342.85M1.1640,429 shs623,890 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELYMEliem Therapeutics+6.38%+6.01%+10.73%+86.24%+906.61%IRDOpus Genetics0.00%+4.62%-4.23%-14.11%+350.23%LPTXLeap Therapeutics0.00%0.00%0.00%0.00%+204,999,900.00%UPBUpstream Bio+0.32%+6.76%-24.49%-33.26%-41.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELYMEliem Therapeutics 0.00N/AN/AN/AIRDOpus Genetics 2.94Moderate Buy$10.77163.95% UpsideLPTXLeap Therapeutics 1.00SellN/AN/AUPBUpstream Bio 2.43Hold$33.17424.79% UpsideCurrent Analyst Ratings BreakdownLatest LPTX, ELYM, IRD, and UPB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026IRDOpus Genetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/18/2026IRDOpus Genetics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $13.006/17/2026IRDOpus Genetics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/17/2026IRDOpus Genetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/16/2026IRDOpus Genetics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/15/2026IRDOpus Genetics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$11.006/12/2026UPBUpstream Bio JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$35.00 ➝ $8.006/10/2026IRDOpus Genetics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/4/2026IRDOpus Genetics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/4/2026IRDOpus Genetics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/3/2026UPBUpstream Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AIRDOpus Genetics$14.20M23.72N/AN/A$0.22 per share18.55LPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/AUPBUpstream Bio$2.85M120.68N/AN/A$6.29 per share1.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELYMEliem Therapeutics-$35.12M-$0.53N/AN/AN/AN/A-47.03%-45.97%N/AIRDOpus Genetics-$49.59M-$1.33N/AN/AN/A-892.36%-338.88%-191.21%8/12/2026 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.22N/AN/AN/AN/A-247.44%-146.51%N/AUPBUpstream Bio-$143.44M-$2.91N/AN/AN/A-4,718.96%-43.82%-42.27%8/5/2026 (Estimated)Latest LPTX, ELYM, IRD, and UPB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026UPBUpstream Bio-$0.73-$0.7470-$0.0170-$0.75$1.03 million$1.03 million5/12/2026Q1 2026IRDOpus Genetics-$0.16-$0.75-$0.59-$0.75$2.93 million$2.16 million3/26/2026Q4 2025UPBUpstream Bio-$0.73-$0.7860-$0.0560-$0.78$0.52 million$0.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthELYMEliem TherapeuticsN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELYMEliem TherapeuticsN/A60.4160.41IRDOpus GeneticsN/A7.137.13LPTXLeap TherapeuticsN/A1.341.34UPBUpstream BioN/A23.1423.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELYMEliem Therapeutics69.76%IRDOpus Genetics14.97%LPTXLeap Therapeutics30.46%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipELYMEliem Therapeutics4.70%IRDOpus Genetics11.70%LPTXLeap Therapeutics4.30%UPBUpstream Bio16.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableIRDOpus Genetics1482.57 million72.91 millionN/ALPTXLeap Therapeutics4041.44 million39.66 millionN/AUPBUpstream Bio3854.42 million45.46 millionN/ALPTX, ELYM, IRD, and UPB HeadlinesRecent News About These CompaniesIs Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?June 23 at 12:11 PM | insidermonkey.comUpstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First PatientsJune 19, 2026 | businesswire.comUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the ...June 14, 2026 | markets.businessinsider.comUpstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key SymptomsJune 14, 2026 | quiverquant.comQUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026June 14, 2026 | globenewswire.comKBRA Assigns Preliminary Ratings to OBX 2026-AHC2 TrustJune 12, 2026 | businesswire.comUpstream Bio Launches $150 Million At-The-Market ProgramJune 11, 2026 | theglobeandmail.comUpstream Bio Shareholders Elect Directors, Ratify 2026 AuditorJune 10, 2026 | tipranks.comUpstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comUpstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug ...June 8, 2026 | enidnews.comEUpstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026June 8, 2026 | globenewswire.comUpstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 3, 2026 | globenewswire.comUpstream Bio: The Reset Is The Opportunity, Initiating At BuyMay 29, 2026 | seekingalpha.comUpstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at ...May 18, 2026 | markets.businessinsider.comUpstream Bio Announces Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps and Comorbid AsthmaMay 18, 2026 | quiverquant.comQUpstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International ConferenceMay 18, 2026 | globenewswire.comLifeSci Capital Reaffirms Their Buy Rating on Upstream Bio, Inc. (UPB)May 17, 2026 | theglobeandmail.comUpstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue EstimatesMay 13, 2026 | zacks.comUpstream Bio Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 13, 2026 | globenewswire.comUpstream Bio stellt neue Daten zu Verekitug auf Fachkonferenz vorApril 17, 2026 | de.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAST SpaceMobile Announces Launch Date for Its Next 3 BlueBird SatellitesBy Jessica Mitacek | June 16, 2026AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in FocusBy Jessica Mitacek | May 26, 2026AST SpaceMobile’s SpaceX Catalyst Could Come With a Volatility WarningBy Jessica Mitacek | June 10, 2026Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround ProgressBy Jennifer Ryan Woods | June 11, 2026Fifth Third’s Big Bet Is OnBy Peter Frank | June 4, 2026LPTX, ELYM, IRD, and UPB Company DescriptionsEliem Therapeutics NASDAQ:ELYM$12.18 +0.73 (+6.38%) As of 06/22/2026Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Opus Genetics NASDAQ:IRD$4.08 0.00 (0.00%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$4.23 +0.15 (+3.70%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Leap Therapeutics NASDAQ:LPTXLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Upstream Bio NASDAQ:UPB$6.32 +0.02 (+0.32%) As of 06/23/2026 04:00 PM EasternUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
